ANOVA revealed the protective efficacy of 0.02% VC (T3) against 0.2% EMS (T1)-treated series at 24 and 96 h ( a ¼Po0.05), and of 0.05% BC ( a ¼Po0.05) (T7) against 0.2% EMS plus 1% Alc (T6) treated at 48 and 96 h with regard to micronucleated erythrocytes (MNE)
(Histogram 1b in Appendix A).